To stay on antipsychotics or not to stay on antipsychotics? A longstanding...
Joe Pierre considers a recent network meta-analysis on continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable. The...
View ArticleDo different groups of people with schizophrenia respond differently to...
Murtada Alsaif considers a systematic review and meta-analysis published in the Lancet Psychiatry exploring the response of different subgroups of patients with schizophrenia to different antipsychotic...
View ArticleUncertainties about stopping or reducing antipsychotics as shared by families
Amelia Talbot considers a qualitative study that explores family members’ perspectives on reducing or discontinuing antipsychotic medication. The post Uncertainties about stopping or reducing...
View ArticleOptimal antipsychotic dosing in first-episode schizophrenia: how much is too...
Joe Pierre reports on the first published study exploring the relationship between antipsychotic dose and risk of relapse in first episode schizophrenia, which suggests that standard antipsychotic...
View ArticlePredicting treatment-resistant psychosis using routine clinical measures
Lorna Staines summarises a recent study on predicting treatment-resistant psychosis, which suggests that future risk prediction efforts should seek to consider routinely collected data. The post...
View ArticleAntipsychotics and risk of violence and suicide in people diagnosed with...
A group of MSc students from UCL summarise a study examining the links between antipsychotics, risk of violent crimes and suicidal behaviour in people diagnosed with a 'personality disorder'. The post...
View ArticleCognition and heterogeneity in First-Episode Psychosis before antipsychotic...
Ana Veic looks at an updated systematic review which suggests that patients with psychosis display cognitive difficulties very early in the disease process, and concludes this variation in cognitive...
View ArticlePsychotropic medication during pregnancy: new umbrella review finds no...
Flo Martin summarises a recent umbrella review which finds that we still have limited knowledge about the safety of psychotropic drug use in pregnancy. The post Psychotropic medication during...
View ArticleThe role of the gut microbiome in treatment-resistant schizophrenia
Nuala Murray explores a recent Australian case-control study that looks at the associations between changes in gut microbiota and schizophrenia diagnosis, treatment resistance, and clozapine response....
View ArticleContinuing antipsychotic medication during pregnancy associated with reduced...
Shuichi Suetani and Sarah Thomas highlight new research from Korea which suggests that antipsychotic medications do seem to help reduce the relapse of schizophrenia in pregnant women. The post...
View ArticleQuetiapine may pip lithium to the post for augmentation in ‘treatment...
Kirsten Lawson and Douglas Badenoch review the new randomised controlled trial by Cleare et al, published today in The Lancet Psychiatry, directly comparing the clinical and cost effectiveness of...
View ArticleLithium is best at decreasing the risk of depression-related hospitalisation...
This Swedish cohort study, blogged by Duncan Swiffen, is yet more evidence for lithium as an excellent treatment for people with bipolar disorder. This time it comes out on top in terms of preventing...
View ArticleProbiotics for bipolar disorder and schizophrenia
Mary Butler explores a recent randomised controlled trial of probiotic formulations for patients with bipolar disorder or schizophrenia spectrum disorder. The post Probiotics for bipolar disorder and...
View ArticleAnticholinergics are associated with worse cognition: it’s time to take a...
Eleanor Dawkins explores a new review and meta-analysis suggesting that cognitive impairment is linked with anticholinergic medication in psychosis, providing grounds for more careful monitoring and...
View Article